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Multiple TREX mRNA export complex subunits (e.g., THOC1, THOC2, THOC5,
THOC6, THOC7) have now been implicated in neurodevelopmental disorders (NDDs),
neurodegeneration and cancer. We previously implicated missense and splicing-
defective THOC2 variants in NDDs and a broad range of other clinical features. Here
we report 10 individuals from nine families with rare missense THOC2 variants including
the first case of a recurrent variant (p.Arg77Cys), and an additional individual with
an intragenic THOC2 microdeletion (Del-Ex37-38). Ex vivo missense variant testing
and patient-derived cell line data from current and published studies show 9 of the
14 missense THOC2 variants result in reduced protein stability. The splicing-defective
Frontiers in Molecular Neuroscience | www.frontiersin.org 1 February 2020 | Volume 13 | Article 12
Kumar et al. New THOC2 Variants in NDDs
and deletion variants result in a loss of small regions of the C-terminal THOC2 RNA
binding domain (RBD). Interestingly, reduced stability of THOC2 variant proteins has
a flow-on effect on the stability of the multi-protein TREX complex; specifically
on the other NDD-associated THOC subunits. Our current, expanded cohort
refines the core phenotype of THOC2 NDDs to language disorder and/or ID,
with a variable severity, and disorders of growth. A subset of affected individuals’
has severe-profound ID, persistent hypotonia and respiratory abnormalities. Further
investigations to elucidate the pathophysiological basis for this severe phenotype
are warranted.
Keywords: mRNA export, THOC2, intellectual disability, neurodevelopmental disorders, microdeletion
INTRODUCTION
Neurodevelopmental disorders (NDDs) caused by genetic,
epigenetic and environmental factors are clinically
heterogeneous conditions affecting the central nervous system
in children and include intellectual disability (ID), epilepsy,
autism and cerebral palsy. NDDs affect more than 3% of
children worldwide. Genetic causes are attributed to variants
at over 1,000 loci and include single nucleotide changes (single
nucleotide variants, SNV; coding and non-coding variants)
and larger losses, gains or rearrangements (structural variants;
Tarlungeanu and Novarino, 2018).
Many molecular causes of NDDs disrupt diverse cellular
pathways, particularly affecting neuronal development,
proliferation and/or migration of cells to cause learning
and behavioral disabilities (Srivastava and Schwartz, 2014).
One such pathway—that has been the focus of our ongoing
investigations—is of the highly conserved TREX (TRanscription-
EXport) mRNA export pathway. Multiple TREX complex
subunits (e.g., THOC1, THOC2, THOC5, THOC6, and
THOC7) have been implicated in NDDs and human disease
(Kumar et al., 2015, 2018; Heath et al., 2016; Amos et al., 2017;
Mattioli et al., 2019). TREX-mediated mRNA export from the
nucleus to the cytoplasm is a complex and highly conserved
pathway in all eukaryotes. The TREX complex is composed of
a THO sub-complex of a set of six stoichiometric and stable
subunits (THOC1-3, 5–7) and accessory proteins (UAP56,
UIF, Aly, CIP29, PDIP3, ZC11A, SRRT, Chtop; Heath et al.,
2016). THOC subunits are ubiquitously expressed, including in
the human brain (Uhlén et al., 2015). The TREX complex has
critical roles in developmental processes such as pluripotency
maintenance and hematopoiesis as well as in gene regulation,
3′ mRNA processing, stress responses, mitotic progression and
genome stability in mammalian cells (Mancini et al., 2010;
Yamazaki et al., 2010). We have previously reported genetic
and molecular evidence implicating a large number of missense
and splicing-defective variants in THOC2–which codes for the
largest subunit of the TREX mRNA export complex—in NDDs
(Mental retardation, X-linked 12/35 MIM 300957; Kumar et al.,
2015, 2018). Here we present genetic and molecular evidence on
a set of novel THOC2 variants, and using aggregate data, refine
the core clinical phenotype of THOC2 NDDs.
MATERIALS AND METHODS
Clinical Studies
Through direct contact with clinicians, facilitated by the
genotype-phenotype database DECIPHER and the Human
Disease Gene Web series, where we moderate a THOC2-
related disorder site1, 10 individuals from 9 families were
identified with rare (absent from gnomAD 2.1) missense variants
or an intragenic microdeletion. Eight of these variants were
novel and one recurrent (p.Arg77Cys) that was a maternally
inherited in individual 8 as previously reported by us (detailed
in Supplementary Data; Kumar et al., 2018). In our previous
report, we designated p.Arg77Cys as a variant of uncertain
clinical significance in the absence of functional studies at the
time (Kumar et al., 2018). All families consented to publication
of de-identified clinical information, neuroimaging and, for
seven families, clinical photographs, in line with local ethics
board regulations. The variants have been submitted to ClinVar2;
accession numbers SCV001132790-SCV001132797.
Molecular Studies
RNA extraction and RT-qPCR (primers listed in Supplementary
Tables S1, S2) were performed as reported previously (Kumar
et al., 2015). We used THOC2 Del-Ex37-38 (lymphoblastoid
cell lines, LCLs and skin fibroblasts) and p.Asn666Asp (skin
fibroblasts) cells from the affected individuals and their carrier
heterozygous mothers. However, we used THOC2 p.Arg77Cys
and p.Tyr881Cys variant LCLs of only probands. THOC2 Del-
Ex37-38 (LCLs and skin fibroblasts) cDNAs (generated by
reverse transcribing the total RNAs with Superscript IV
reverse transcriptase; Life Technologies, VIC, Australia) were
amplified using KAPA HiFi PCR Kit with GC buffer (Kapa
Biosystems, IN, USA) and hTHOC2-4326F/P276 and hTHOC3-
3′UTR-R2/P392 primers (Supplementary Table S1) at 95◦C
for 3 min, 35 cycles of 98◦C-10 s, 59◦C-10 s, 72◦C-
80 s, incubation at 72◦C for 10 min, gel purified (Qiagen
MinElute Gel Extraction kit; Qiagen, Victoria, Australia)
and Sanger sequenced using the same primers. Genomic
deleted region in THOC2 Del-Ex-37-38 carrier mother and
1https://humandiseasegenes.nl/thoc2/
2https://www.ncbi.nlm.nih.gov/clinvar/?term=‘‘GOLD%20service%2C
%20Hunter%20New%20England%20Health’’[submitter]+AND+‘‘THOC2’’[gene]
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affected son was identified by PCR amplification of the
target regions from their blood gDNAs using LongAmp
Hot Start Taq 2× Master Mix (Promega, Alexandria, NSW,
Australia) and hTHOC2-4460-F/P390 and hTHOC2-gDNA-
R1/P415 primers (Supplementary Table S1) at 94◦C for
30 s, 35 cycles of 94◦C-15 s, 64◦C-15 s, 65◦C-8 min
30 s, incubation at 65◦C for 10 min. Appropriate PCR
products were gel-purified (Qiagen MinElute Gel Extraction
Kit) and Sanger sequenced using hTHOC2-gDNA-F7/P421 and
hTHOC2-gDNA-R7/P422 primers (Supplementary Table S1).
Cellular Studies
We performed THOC2 immunofluorescence staining in
Del-Ex37-38 and p.Asn666Asp skin fibroblasts using two
anti-THOC2 antibodies; anti-THOC2-I to region between
amino acids 1,400–1,450 (Bethyl Laboratories A303-629A,
Montgomery, TX, USA) and anti-THOC2-II to a region between
amino acids 1543–1593 (Bethyl Laboratories A303-630A) of the
THOC2 protein. Both the antibodies were used for detecting
the THOC2 protein in Del-Ex37-38 affected individuals and
his carrier heterozygous mother fibroblasts but only anti-
THOC2-I for detecting the THOC2 p.Asn666Asp in the affected
individuals and his carrier heterozygous mother fibroblasts.
Western Blotting
The Epstein–Barr virus (EBV)-immortalized B-cell lines
(LCLs) established from peripheral blood lymphocytes
of affected individuals and controls were maintained in
RPMI1640 supplemented with 10% fetal bovine serum, 2 mM
L-glutamine and 1% Penicillin-Streptomycin at 37◦C with 5%
CO2. Affected individual-derived fibroblasts were cultured in
Dulbecco’s modified Eagle’s medium (Sigma) containing 10%
fetal bovine serum (Life Technologies), 2 mM L-glutamine,
and 1% Penicillin-Streptomycin at 37◦C with 5% CO2. Total
fibroblast proteins were extracted in 50 mM Tris-HCl pH
7.5, 150 mM NaCl, 0.1% Triton-X-100, 1 mM EDTA, 50 mM
NaF, 1× Protease inhibitor/no EDTA cocktail and 0.1 mM
Na3VO4 and LCLs in 50 mM Tris-HCl pH 7.5, 5 mM EDTA,
50 mM KCl, 0.1% NP-40 and 1× Protease inhibitor/no EDTA
cocktail (Roche protease inhibitor cocktail; Sigma–Aldrich,
Castle Hill, NSW, Australia) by low frequency sonication for 12 s
and centrifugation at 13,000× g. Proteins were assayed using
Pierce BCA Protein Assay Kit (Thermo Scientific) according
to manufacturer’s protocol. Eight to Ten microgram of protein
was resolved on NuPAGE 3–8% Tris-Acetate gel (THOC2) or
8% SDA-PAGE (Laemmli, 1970), transferred to nitrocellulose
membranes and western blotted with the following antibodies:
anti-THOC1 (Bethyl Laboratories A302-839A), anti-THOC2
(Bethyl Laboratories A303-630A and A303-629A), anti-THOC3
(HPA044009; Sigma–Aldrich, Castle Hill, NSW, Australia),
anti-THOC5 (Bethyl Laboratories A302-120A), anti-β-Tubulin
(Ab6046; Abcam, Melbourne, VIC, Australia) and polyclonal
goat anti-rabbit IgG/HRP (Dako; P0448) as secondary antibody.
Signal was detected by Clarity Western ECL Substrate (BIO-
RAD 170-5061) and captured using Gel documentation System
(BIO-RAD, Gladesville, NSW, Australia).
In silico Pathogenicity Prediction
We used CADD v1.3 (Kircher et al., 2014), SIFT (Sim et al.,
2012), Provean (Choi and Chan, 2015), GERP++ (Davydov et al.,
2010), PhyloP (Pollard et al., 2010), gnomAD frequency (v2.1.1;
Karczewski et al., 2019), Polyphen2 (Adzhubei et al., 2010),
MutPred2 (Pejaver et al., 2017), VEST3 (Carter et al., 2013),
and Mutation Assessor Score and Pred (Reva et al., 2011) tools
for in silico prediction of the pathogenicity of different variants
(Table 1).
RESULTS
Identification of THOC2 Variants
We previously implicated missense and splicing-defective
THOC2 variants in NDDs with a broad range of clinical
features (Kumar et al., 2015, 2018). Here we report
10 previously unreported affected individuals with THOC2
variants, including the first case of a recurrent THOC2
variant (c.229C>T; p.Arg77Cys). We also identify a
novel intragenic THOC2 microdeletion (Del-Ex37-Ex38)
[NM_001081550.2 c.4678–572_4782 + 1215; p.(1559fs16)]
(Tables 1, 2, Figures 1, 2). These variants were identified from
either whole exome (WES) or whole-genome sequencing (WGS)
of the affected individuals and confirmed by Sanger sequencing
of the PCR amplified variant-carrying region from gDNAs of the
parents and the affected individuals (detailed in Supplementary
Data). The missense THOC2 variants affect amino acids that
are highly conserved (Supplementary Figure S1), are absent
in the gnomAD database and are predicted to be pathogenic
based on a number of in silico analyses tools (Table 1). We have
also performed cellular and molecular investigations on variants
p.Arg77Cys, p.Tyr881Cys, p.Asn666Asp and Del-Ex37-38, for
which we had access to affected individual-derived cells (Table 1;
also see below).
Clinical Presentations
The clinical phenotype of affected individuals with THOC2
variants in this cohort is presented in Table 2 and summarized
in Figures 2A,B. The available photographs are shown in
Figure 2C. Additional information relating the clinical features
is included in case reports in the Supplementary Data and
Supplementary Table S2, using an HPO (Human Phenotype
Ontology) term framework (Köhler et al., 2019). The main
phenotypic features were compared to the individuals reported
previously by our group (Table 2, Kumar et al., 2015, 2018).
This allowed us to make some general observations about the
clinical phenotype of the n = 38 individuals with THOC2
variants (this cohort; Kumar et al., 2015, 2018). First, there is
no clear genotypic-phenotypic correlation between the severity
or spectrum of phenotypic differences and either the type of
genetic variant (missense, splicing-defective or microdeletion)
or the part of the protein affected by the variant (Table 2).
Second, compared to the first published cohort, which consisted
of hemizygous affected males in multi-generational families, the
second and this cohort also include many males with de novo
THOC2 variants or THOC2 variants in siblings which, on further
segregation, were shown to be de novo in the heterozygous
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mother. The initial cohort described males with typically mild to
moderate ID. Of 20 individuals, 30% (6/20) had borderline-mild
ID, 55% (11/20) moderate ID and only 15% (3/20) severe ID
(Kumar et al., 2015). In contrast, our last (Kumar et al., 2018) and
current cohort includes a higher proportion [75% this cohort;
62.5% (Kumar et al., 2018)] of males with severe to profound ID.
In striking contrast to our overall findings is individual 4 with
the p.Tyr881Cys variant. This male, in whom pathogenicity of
p.Tyr881Cys variant is supported by evidence from functional
studies (Figures 5B,C: detailed results below), is unique in our
cohort as having no evidence of general cognitive dysfunction.
On psychometric testing, he had a performance IQ of 104, within
the normal range. He did have significant language disorder,
with a formal diagnosis of speech apraxia. At the age of 5,
he could effectively communicate by sign language. He has a
history of mild gross motor delay. Therefore, this publication
clarifies that the range of cognitive disability in THOC2-related
disorder is very broad—ranging from a normal IQ to a profound
ID (Figure 2A).
Third, data in Figure 2B and Table 2 suggest that THOC2-
related disorder should be considered a multi-systemic disorder
in a significant proportion of individuals. The most common
extra-neurological feature is disorders of growth. Growth
disorders are common across the whole expanded cohort
(Figure 2B); a half (52%) have persistent short stature, a
third (34%) are microcephalic and 29% have intrauterine
growth restriction (IUGR). There was no relationship between
IUGR in the offspring and carrier status in the mother.
26% of the expanded cohort have increased body weight,
with obesity in older males particularly noted. Congenital
anomalies of the cardiorespiratory, genitorenal and skeletal
systems, severe feeding difficulties and gastroesophageal reflux,
and visual and hearing impairments are present in a significant
proportion (10–30%). Therefore, comprehensive evaluation
including detailed systems review by a pediatrician, cardiac
echocardiogram, hearing screening and ophthalmological review
in all newly diagnosed patients is highly recommended.
Photographs where available are shown in Figure 2C. As was
the case in our previous publications, an easily recognizable
facial gestalt is not apparent, although children with a more
severe phenotype (Individuals 1, 6, 8 and 9) have downturned
corners of their mouth and deep-set almond-shaped eyes: a facial
appearance, which may reflect reduced tone.
Fourth, a more complex neuromuscular phenotype is
emerging in a proportion of the cohort: that of severe to profound
ID, persistent muscular hypotonia, recurrent aspiration and
respiratory tract infections, excessive salivation and an increased
risk of congenital anomalies, including laryngo/tracheomalacia,
cardiac and palatal anomalies. This phenotype was present
in the individual with p.Arg77Cys variant for which initial
functional studies using exogenous THOC2 variant expression
in HEK293T cells were not conclusive (Kumar et al., 2018).
We classified this as a variant of uncertain significance, also
in view of this patient’s phenotype, which was quite different
from the majority of the cohort. We are now more confident
that this variant is pathogenic. The variant is recurrent and de
novo in individual 1 in this cohort and molecular studies from
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TABLE 2 | Summary of clinical data of THOC2 variants.
This Cohort
Individual Individual 1 Individual 2 Individual 3 Individual 4 Individual 5a Individual 5b Individual 6 Individual 7 Individual 8 Individual 9 Percentage Percentage
Variant details c.229C>T:p. c.1996A>G: c.2170A>G: c.2642A>G: c.2942G>A: c.2942G>A: c.3223C>T: c.3300G>T: c.4646A>G: Nullizygosity this cohort total cohort
Arg77Cys Asn666Asp p.Lys724Glu p.Tyr881Cys p.Cys981Tyr p.Cys981Tyr p.Arg1075Trp p.Trp1100Cysp.Lys1549Arg for the last (n = 10) (n = 38)
two coding
exons
Gender Male Male Male Male Male Male Male Male Male Male 100% (10/10) 97% (37/38)
Age (years) 6 5 20 5 15 10 2.5 4.5 2 11 2–20 years 2–61 years
Perinatal
features
Prematurity No No Yes No No No No No No No 10% (1/10) 18% (6/34)
Low birth
weight (<2.5kg)
Yes No Yes No No No No No Yes No 30% (3/10) 29% (10/34)
Neurologic
features
Intellectual
disability
Yes—
Profound
Yes—
Profound
Yes—
Severe
No Yes—
Severe
Yes—
Severe
Yes—Mod+ Yes—
Severe
Yes—
Severe
Yes—Mod+ 9/10 (90%)
[22% mod;
78% severe
to profound]
97% (37/38)
[16%
borderline-mild;
27% moderate;
39% severe-
profound]
Speech delay Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 100% (10/10) 82% (31/38)
Hypotonia Yes No Yes No Yes Yes Yes Yes Yes Yes 80% (8/10) 61% (22/36)
Spasticity No No Yes No Yes No No No No Yes 30% (3/10) 13% (5/38)
Hyperkinesia Yes No No No No No No No No No 10% (1/10) 21% (8/38)
Tremor No No No No No No No No No No 0% (0/10) 26% (10/38)
Epilepsy Yes—IS and
tonic/myoclonic
No No No No No Yes—IS No Suspected Suspected 20% (2/10)
confirmed,
20% (2/10)
suspected
21% (8/38)
confirmed, 8%
(3/38)
suspected
Gait
disturbances
Non
ambulatory,
hyperkinetic
No Yes—dystonia,
spasticity
No Yes—poor
balance and
coordination,
weakness,
spasticity
Yes—poor
balance and
coordination,
weakness,
spasticity
Non
ambulatory
Non
ambulatory
Non
ambulatory
Appendicular
spasticity
80% (8/10) 48% (18/38)
Behavior
problems
No No No No No Yes No No No No 10% (1/10) 39% (15/38)
Anxiety No No No No No No No No No No 0% (0/10) 5% (2/38)
Depression No No No No No No No No No No 0% (0/10) 5% (2/38)
Brain MRI/CT Delayed
myelination,
ventriculomegaly,
small
midbrain
Abnormal
CNS
myelination
Ventriculomegaly Normal ND Cerebellar
atrophy &
periventricular
changes
Gray matter
heterotopia
Delayed
myelination,
right
perisylvian
polymicrogyria,
short corpus
callosum
Ventriculo
megaly,
small midbrain,
abnormal
cerebellar
vermis
Abnormal
myelination
89% (8/9) 47% (15/32):
43%
ventriculomegaly
or cerebral
atrophy; 48%
white matter
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TABLE 2 | Continued
This Cohort
Individual Individual 1 Individual 2 Individual 3 Individual 4 Individual 5aIndividual 5b Individual 6 Individual 7 Individual 8 Individual 9 Percentage Percentage
Variant details c.229C>T:p. c.1996A>G: c.2170A>G: c.2642A>G: c.2942G>A: c.2942G>A: c.3223C>T: c.3300G>T: c.4646A>G: Nullizygosity this cohort total cohort
Arg77Cys Asn666Asp p.Lys724Glup.Tyr881Cys p.Cys981Tyr p.Cys981Tyr p.Arg1075Trp p.Trp1100Cys p.Lys1549Arg for the last (n = 10) (n = 38)
two coding
exons
abnormality;
19% cerebellar
abnormality;
19%
abnormality of
neuronal
migration
Growth parameters
Microcephaly (≤3%) Yes Yes Yes No No No Yes No No Yes 50% (5/10) 34% 13/38
Short stature (≤3%) Yes No Yes No Yes Yes No No Yes No 50% (5/10) 52% 20/38
Overweight (BMI≥25) No No No No No No No No No No 0% (0/10) 26% (10/38)
Other features
Visual abnormality Yes—high
myopia
No Yes—visual
impairment
No No No Yes—visual
impairment,
unilateral
coloboma
No Yes—
bilateral
exotropia
Yes—
blepharophimosis,
exotropia
50% (5/10) 9/38 (24%)
[ 11%
strabismus; 5%
nystagmus]
Hearing
abnormality
Yes—
bilateral
OME
Yes—SNHL No No No No Yes—mixed No No Yes—mixed 40% (4/10) 6/38 (16%)[8%
OME; 8%
SNHL]
Genitorenal
abnormality
Yes—
recurrent UTI
Yes—
cryptorchidism
No No No No No No Yes—
cryptorchidism
30% (3/10) 10/38 (26%)
[19%
cryptorchidism]
Gastrointestinal
abnormality
Yes—severe
feeding
difficulties,
drooling, GORD
: g-tube fed
No Yes—severe
feeding
difficulties,
GORD
No Yes—
drooling
No Yes—severe
feeding
difficulties,
GORD
Yes—severe
feeding
difficulties,
chronic
constipation
Yes—severe
feeding
difficulties,
oropharangeal
dysplasia,
drooling,
GORD:
g-tube fed
Yes—feeding
difficulties
70% (7/10) 7/38 (18%)
[18% feeding
difficulties; 5%
dysphagia,
11% GORD,
11% drooling]
Respiratory
abnormality
Yes— CLD +
oxygen
dependency
No Yes—CLD No No No Yes—
tracheomalacia
Yes—
recurrent
LRTI
Yes— recurrent
apnea and
bradycardia,
Yes—recurrent
LRTI
60% (6/10) 10/38 (26%)
[11% laryngo or
tracheomalacia;
5% apnoea;
11% abnormal
lung
morphology]
Skeletal
abnormality
Yes—aquired
coxa valga
No Yes—
kyphosis
No No No No Yes— scoliosis;
DDH
No Yes—scoliosis 40% (4/10) 6/38 (16%)[5%
subluxation of
the hips and
joint laxity]
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patient-derived cell lines available from this second family are
consistent with reduced protein levels. Both individuals with
the p.Arg77Cys variant has strikingly overlapping phenotypes
(see Supplemental Data for detailed case reports). Individuals
6, 8 and 9 from the current cohort also have similarities to
this phenotype. This more severe phenotype is also frequently
associated with neuroradiological abnormalities and an increased
chance of a seizure disorder. Seizure disorder, although not
very common over the whole cohort (Figure 2B: 21%), can
be problematic – with a severe developmental and epileptic
encephalopathy picture, commonly including infantile spasms.
Therefore, the clinicians should have a low threshold for
investigating neurological symptoms or signs with an EEG and
MRI brain.
Fifth, although for many individuals the phenotype is static,
a more complex neurological phenotype also emerges with
age in several males; in the expanded cohort 13% develop
hypertonia and spasticity or contractures, and 53% have some
abnormality of motor coordination, stereotypic or involuntary
movements. In the current cohort, three individuals had
received an additional diagnosis of cerebral palsy. Of the nine
affected individuals included in this cohort, cases 1, 4, 5, 6,
7 have had multi-timepoint MRI neuro-imaging reviewed by
a single Neuroradiology Attending Consultant with dedicated
pediatric expertise (data not shown). Although no unifying
neuroradiological abnormalities were delineated from this small
cohort, one affected individual demonstrated interval cerebellar
hemispheric volume loss after a 6-year period, and another
demonstrated volume loss of the corpus callosum and mild
reduction in myelination at an early post-natal 4-month scan.
A further patient had reported features of nodular heterotopia
although this imaging was not available for review. No other
definitive migrational anomaly, midline defect or development
abnormality was identified. The potential implications on white
matter development and degeneration in this cohort require long
term follow-up imaging.
Lastly, all heterozygous female carriers in this cohort had
normal intelligence, as was the case for the entire cohort,
with the exception of the one female reported to date with
a de novo THOC2 variant with a developmental and epileptic
encephalopathy (Kumar et al., 2018).When tested, asymptomatic
female carriers are highly skewed for X inactivation (Kumar et al.,
2015, 2018).
In summary, this expanded cohort has clarified that the core
phenotype of THOC2 related disorder in hemizygous males is
that of language disorder and ID, with a wide variability in
severity, and that disorders of growth are common, and multi-
systemic involvement is present in a significant proportion.
A subpopulation of patients has a very severe phenotype
with severe-profound ID, persistent hypotonia, respiratory
abnormalities and a higher chance of other congenital anomalies.
Some affected males show the progression of neurological
symptoms and progressive neuroradiological features. Further
research to explore the underlying pathophysiological basis
for these more severe phenotypes is warranted, but likely
reflect the involvement of THOC2 in multi-organ development
and function.
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FIGURE 1 | New THOC2 variants (purple). These include the first Arg77Cys recurrent (boxed) and Del-Exon-37-38 variants (red bold). Previously published THOC2
variants (black) and structural features are also shown (Kumar et al., 2015, 2018).
Molecular Studies
We used primary skin fibroblasts and/or immortalized
B-lymphocytes (LCLs) derived from affected individuals
and where available, also their heterozygous carrier mothers.
Del-Ex37-38 THOC2 Variant
We found an affected male with deletion of THOC2 Ex37-38
(NM_001081550.2) as identified bymassively parallel sequencing
(see Figure 3). We have subsequently validated this as a
2.4 kb X-chromosome gDNA microdeletion (encompassing
Ex37-38 sequence) which was also present in his carrier
mother (Figure 4). In addition, we PCR amplified the
Ex35-Ex39 coding region from cDNAs prepared by reverse
transcribing the LCL and fibroblast mRNAs from the affected
individual and his normal carrier mother (Figure 3C). Sanger
sequencing of the amplified products showed deletion of Ex37-
38, but not Ex39 coding sequences, in the affected individual
(Figures 3B,C). The carrier mother’s cells showed mRNAs
with Ex37-38 sequences consistent with her X-inactivation
skewing (10:90; Figures 3A–C). We detected a slightly smaller
THOC2 protein (due to Ex37-38-encoded C-terminal 34 amino
acid deletion) in affected son’s LCLs and fibroblasts but normal
full-length THOC2 protein in the unaffected carrier mother on
western blots probed with anti-THOC2-I antibody that binds
to a region between amino acids 1,400–1,450 coded by Ex32-
33 mRNA sequences (compare lanes 1 and 2, upper panel,
Figure 5A and lanes 3 and 4, Figure 5B). Notably, C-terminal
THOC2 truncated protein levels were higher in both the affected
LCLs and fibroblasts (Figures 5A,B). As expected, the anti-
THOC2-II antibody that binds to a region between amino acids
1543–1593 coded by Ex37-38 mRNA sequences (lower panel)
did not detect the THOC2 protein in affected son’s LCLs and
fibroblasts that express a C-terminally-deleted THOC2 protein.
This antibody however detected THOC2 protein in the carrier
mother-derived cells as she expressed normal full-length
THOC2 protein (compare lanes 1 and 2, lower panel, Figure 5A
and lanes 3 and 4, Figure 5B). THOC1 and THOC5 levels
were similar in fibroblasts of the affected son and carrier
mother (Figure 5A). Likewise, anti-THOC2-I antibody detected
nuclear THOC2 protein in both the affected son and carrier
mother’s fibroblasts by immunofluorescence but anti-THOC2-
II antibody, as expected, detected the THOC2 protein in the
mother’s but not son’s fibroblasts (Figures 6A–C). Normal
nuclear THOC2 localization was detected in fibroblasts of the
affected son and carrier mother (Figure 6F). We observed
no significant difference in THOC2 mRNA level in LCLs and
fibroblasts of the affected son and carrier mother (Figure 7A).
THOC2 Missense Variants
LCLs were available from affected individuals’ hemizygous
for the p.Arg77Cys and p.Tyr881Cys variants and fibroblasts
from the affected individual and his carrier mother with
the Trp.Asn666Asp variant (Figure 5). p.Arg77Cys and
p.Tyr881Cys THOC2 variants resulted in reduced protein
levels compared to control LCLs (Figures 5B,C). THOC1 and
THOC5 levels were also moderately reduced in these LCLs
(Figures 5B,C). Interestingly, a reduction in p.Arg77Cys
and p.Tyr881Cys THOC2 variant protein levels were similar
to unstable p.Leu438Pro variant THOC2 protein reported
previously (Figure 5C; Kumar et al., 2015). Note that RT-qPCR
assays in p.Arg77Cys and p.Tyr881Cys THOC2 variant
LCLs also showed reduced mRNA expression compared to
unrelated normal controls (Figure 7B). Western blotting on
p.Asn666Asp fibroblasts also showed a small but reproducible
reduction in THOC2 protein and related THO complex
subunits THOC1, THOC3 and THOC5 compared to his
unaffected carrier mother and unrelated normal controls
(Figure 5D). p.Asn666Asp THOC2 reduction was much less
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FIGURE 2 | Clinical presentations of the affected individuals identified so far.
(A) Percentage of individuals with different levels of ID. (B) Percentage of
individuals with common features. (C) Photographs of the affected individuals
in the current cohort.
pronounced than that of highly unstable p.Leu438Pro THOC2 as
well as THOC1 and THOC5 proteins in affected fibroblasts
(Figure 5D). p.Asn666Asp THOC2 localization was not affected
(Figures 6D,E). Levels of mRNA expression in p.Asn666Asp
affected LCLs were similar to that of the patient’s carrier mother
and unrelated controls (Figure 7A).
DISCUSSION
TREX-mediated mRNA export is a fundamental process that
is essential for the export of mRNA from the cytoplasm
to the nucleus to allow translation of the normal level of
protein required for efficient growth and development. We
and others have presented evidence showing that perturbed
mRNA export leads to altered cellular function, thus causing
a range of diseases (Di Gregorio et al., 2013; Kumar et al.,
2015, 2018; Heath et al., 2016; Mattioli et al., 2019). During
the last few years, we have focussed on the association of
variation in the THOC2 gene and NDDs. THOC2 is intolerant
to complete loss of function [probability of loss of function
or pLI = 1; o/e = 0.02 (0.01–0.08): gnomAD v.2.1.1]. We
first reported four THOC2 missense inherited variants in the
affected individuals with variable degrees of ID and commonly
observed features such as speech delay, elevated BMI, short
stature, seizure disorders, gait disturbance, and tremors (Kumar
et al., 2015). In 2018, we reported an additional six affected
individuals from five unrelated families with two de novo
and three maternally inherited pathogenic or likely pathogenic
missense and splicing-defective THOC2 variants. The study
also included a de novo variant in a female with epileptic
encephalopathy. We observed a core ID phenotype and common
behavioral features, infantile hypotonia, gait disturbance and
growth impairment (Kumar et al., 2018). In the current cohort,
we present molecular and clinical findings on ten additional
THOC2 variant individuals, confirming a more severe THOC2-
related phenotype associated with severe hypotonia, respiratory
and other congenital anomalies, and summarize the phenotypic
impact of all THOC2 variants to date in 38 individuals. This
publication, therefore, may serve as the most up to date reference
of this X-linked NDD condition.
Variants in TREX subunit proteins can alter their stability
(Kumar et al., 2015, 2018; e.g., THOC2 ID variants), interaction
(e.g., THOC6 syndromic ID variants; Mattioli et al., 2019)
and/or localization (e.g., THOC6 syndromic ID variants; Mattioli
et al., 2019). We observed reduced levels of p.Arg77Cys
THOC2 (although the stability of this variant exogenously
expressed in HEK293T cells was uninformative, see Figure 3 in
Kumar et al., 2018) and p.Tyr881Cys THOC2 in the affected
LCLs and p.Asn666Asp THOC2 affected fibroblasts (without
THOC2 mislocalization). Variant THOC2 protein reduction
also impacted the THOC1, THOC3 and THOC5 stability
in the variant cells, which is consistent with a number of
reports showing that instability of THO subunits—either by
missense changes or siRNA-mediated knockdown—results in
reduced levels of other THO subunits (Chi et al., 2013;
Kumar et al., 2015, 2018). As the THOC2 mRNA levels
in the affected LCLs or fibroblasts were comparable to the
controls, the reduced THOC2 variant protein levels are most
likely due to enhanced proteasome-mediated degradation of
ubiquitinated THOC2 (Lopitz-Otsoa et al., 2012). Reduced
or depleted THO subunit proteins have been shown to
cause severe to mild nuclear mRNA retention (Chi et al.,
2013) and hence can cause variable molecular and cellular
consequences both in mammalian cells and lower organisms.
For example, THOC2 depletion impacts chromosome alignment,
mitotic progression, and genomic stability in human HeLa
cells (Yamazaki et al., 2010). Thoc2 knockdown in Drosophila
S2 cells inhibits cell proliferation and heat-shock mRNA export
(Rehwinkel et al., 2004). Thoc2 depletion results in a significant
increase in the length of neurites in cultured rat primary
hippocampal neurons and C. elegans thoc2 knockout worms are
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FIGURE 3 | Del-Ex37-38 results in the loss of 34 C-terminal amino acids in the affected individual. (A) Part of the THOC2 gene showing Ex34 to Ex39 and positions
of primers. Ex37-38 deleted mRNA translates a 1575 amino acid protein, lacking 34 C-terminal amino acids but adding 16 amino acids encoded from the 3′ UTR
region of the deleted mRNAs. (B) Sanger sequencing chromatograms of DNA amplified from LCL and fibroblast cDNAs of the affected individual and his
heterozygous unaffected carrier mother using primers P276/P392 located within Ex34 and Ex39. Wild type (1593 amino acid) and C-terminal deleted THOC2 protein
(1575 amino acids) translated from Del-Ex37-38 mRNA is also shown. (C) Ex37-38 coding sequence is deleted in both fibroblast and LCL THOC2 mRNAs of the
affected son but not in the unaffected carrier mother. Total fibroblast and LCL RNAs were reverse transcribed and PCR amplified using primers P276/P392. PCR
products (999 bp from the carrier mother and 876 bp from the affected son) were gel purified and Sanger sequenced using P276 and P392 primers.
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FIGURE 4 | Del-Ex37-38 results from the deletion of approximately 2.4 kb genomic DNA (chrX:122743574-122745939) flanking the Ex37-38. Sequences around
the deleted target region were amplified from the affected son and carrier mother’s blood gDNA using P390/P415 primers using LongAmp Hot Start Taq 2× Master
Mix, resolved on agarose gel and bands a-c were eluted and Sanger sequenced. Positions of the P390/P415 primers and sequencing chromatograms (a–c) around
the deleted gDNA regions are shown.
slow-growing, sterile, have functional defects in specific sensory
neurons and die prematurely (Di Gregorio et al., 2013). Danio
rerio Thoc2 is essential for embryonic development (Amsterdam
et al., 2004). Interestingly, a de novo translocation creating a
PTK2-THOC2 fusion that reduced the expression of the two
genes in a female patient was implicated in cognitive impairment
and cerebellar hypoplasia (also reported in 4/19 of our cases;
Di Gregorio et al., 2013). THOC2 or THOC5 depletion leads to
dedifferentiation of vascular smooth muscle cells, characterized
by increased migration and proliferation (Yuan et al., 2018).
Thoc2 and Thoc5 depletion was shown to cause retention of
self-renewal (Oct4) and pluripotent gene transcripts (Nanog,
Sox2, Esrrb, and Klf4) as well as increased differentiation gene
expression (Cdx2, Gata3 and Gata4) in mouse embryonic stem
cells, resulting in a decrease in cell pluripotency and proliferation
(Wang et al., 2013).
We observed accumulation of 34 C-terminal amino acid
THOC2 truncated protein in Del-Ex37-38 LCLs and fibroblasts
that is similar to the accumulation of 110 C-terminal amino
acid deleted THOC2 protein in fibroblasts of the affected
individual carrying the exon35:c.4450–2A>G splice-variant and
potential loss of the 1,300–1,593 amino acid putative RNA
binding domain (RBD) in a proportion of blood cells with the
exon28:c.3503 + 4A>C defective splice-variant (Kumar et al.,
2018). The truncated proteins in these individuals had normal
nuclear localization. Together, the affected individuals (at least
in Del-Ex37-38 and exon35:c.4450–2A>G splice-variant) not
only have truncated THOC2 protein (where a part of the RBD
is lost) but actually more of it, which may indicate presence
of a degradation signal within this region and/or stabilization
due to structural changes to the THOC2 protein that may or
may not be impacting interactions with other TREX subunits.
That C-terminally truncated THOC2 protein potentially has
perturbed function is consistent with yeast Tho2 studies showing
that Tho2∆1408–1597 (small C-terminal RBD deletion) grows
slower than the wild-type strain and Tho∆1271–1597 (complete
RBD deletion) strain barely grows at restrictive temperature
(Peña et al., 2012).
THOC2 depletion leads to almost complete retention of
mRNAs in the cell nucleus, suggesting that it is an essential
mRNA export factor whose complete knockout can be
potentially toxic to the cell (Chi et al., 2013). We, therefore,
suggest that all the identified THOC2 variants result in partial
loss-of-function that alters normal mRNA export in neuronal
and likely other cells, thereby causing a broad range of clinical
presentations in the affected individuals carrying the THOC2
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FIGURE 5 | THOC2 variant protein analysis in patient-derived cell lines. (A) THOC2 protein in affected son with Del-Ex37-38, unaffected carrier mother and control
fibroblasts. Total protein lysates were western blotted with an anti-THOC2-I antibody that binds to a region between amino acids 1,400–1,450 coded by Ex32-34
mRNA (upper panel) and anti-THOC2-II antibody that binds to a region between amino acids 1543–1593 coded by Ex37-38 mRNA (lower panel). Samples were
probed for β-Tubulin as a loading control. (B) THOC2 protein in p.Arg77Cys, p.Tyr881Cys, affected son with Del-Ex37-38, unaffected carrier mother and control
LCLs. Total protein lysates were western blotted with anti-THOC2-I, anti-THOC2-II, anti-THOC1, anti-THOC5 and anti-β-Tubulin (loading control) antibodies.
Del-Ex37-38 affected fibroblasts (Lane 1 in panel A) and LCLs (Lane 3 in panel B) showing presence of a C-terminally deleted smaller but higher levels of the
THOC2 protein when western blotted with anti-THOC2-I antibody (upper panels) that is absent in the affected fibroblast lysates probed with anti-THOC2-II antibody
(lower panels). However, normal full-length THOC2 protein is present in the carrier mother and controls western blotted with both the anti-THOC2-I and
anti-THOC2-II antibodies (Lane 2 in upper and lower panels in A and Lane 4 in upper and lower panels in B). The p.Arg77Cys and p.Tyr881Cys THOC2 levels are
reduced. (C) THOC2 protein levels in p.Leu438Pro (reported to have reduced protein stability; Kumar et al., 2015), p.Arg77Cys, p.Tyr881Cys, Del-Ex37-38 affected
son, his unaffected carrier mother and control LCLs. Total protein lysates were western blotted with anti-THOC2-II, anti-THOC5 and anti-β-Tubulin (loading control)
antibodies. (D) The p.Asn666Asp levels are moderately reduced in the affected fibroblasts. p.Asn666Asp affected son, his unaffected carrier mother and control
fibroblast total lysates were western blotted with the antibodies as shown. p.Leu438Pro fibroblasts previously reported having reduced THOC2 protein stability were
included as controls (Kumar et al., 2015). Vertical lines on western blot images indicate the site of deleted sample lanes.
variants. However, although THOC2 depletion causes bulk
mRNA nuclear retention in HeLa cells (Chi et al., 2013), whether
THOC2 variants affect—bulk or specific—mRNA export in
neuronal cells has not been elucidated. TREX complex was
originally thought to be a bulk mRNA export pathway but
a number of reports have shown its role in specific mRNA
export. For example, the Thoc1/2 and Thoc5 or Thoc6 are
responsible for nuclear export of only a subset of mRNAs
(e.g., heat shock mRNAs) in Drosophila and mammalian cells,
respectively (Rehwinkel et al., 2004; Katahira et al., 2009;
Guria et al., 2011). Thoc2 and Thoc5 selectively bind
and regulate the export of mRNAs involved in the
maintenance of pluripotency (e.g., Nanog, Sox2, Esrrb, and
Klf4 mRNAs (Wang et al., 2013) and Thoc5 in hematopoiesis
(Mancini et al., 2010).
The published data in conjunction with our molecular
and cellular data, and broader clinical presentations in our
cohort indicate that THOC2 reduction (and consequently
other THO subunits) or potential alterations in TREX subunit
interactions due to intragenic deletion of C-terminal RBD
and/or structural interactions as a result of THOC2 missense
changes result in perturbed mRNA export, causing cellular
dysfunction and NDDs. This view is supported by the published
evidence showing that slight perturbations in mRNA export can
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FIGURE 6 | THOC2 localization is unaltered in variant fibroblasts. THOC2-II
antibody detects THOC2 protein in fibroblasts of the Del-Ex37-38 unaffected
carrier mother (A) but not affected son (not shown, as we detected no
fluorescence signal). However, the THOC2-I antibody detects THOC2 protein
in fibroblasts of unaffected carrier mother (B) and the affected son with
Del-Ex37-38 (C). Localization p.Asn666Asp THOC2 protein in fibroblasts of
an affected son (D), his unaffected carrier mother (E) and control (F).
lead to NDDs (Beaulieu et al., 2013; Kumar et al., 2015, 2018;
Mattioli et al., 2019), neurodegenerative disease (Woerner
et al., 2016) and cancer (Domínguez-Sánchez et al., 2011).
There are also examples showing how variants in the
human mRNA export mediator GLE1 result in a severe
fetal motor neuron disease (Nousiainen et al., 2008) and
amyotrophic lateral sclerosis (ALS; Kaneb et al., 2015), and
toxic CUG expansion in the 3′ untranslated region of the
DM protein kinase mRNA can cause myotonic dystrophy
type I by impairing RNA transport out of the nucleus
(Brook et al., 1992).
Based on clinical and, where available, molecular data on
38 individuals, we have come to a realization that the THOC2-
linked NDDs can present with highly variable phenotypes.
Intriguingly, we also identify a case of severe expressive dysphasia
without obvious intellectual impairment. This particular case and
observation still awaits replication and as such further validation.
In hindsight, it is perhaps not surprising that even subtle
perturbation to a crucial cellular mechanism like TREX mRNA
export can yield complex and often variable clinical presentations
which can not only be driven by the THOC2 gene variation itself,
but can also be modified by genome-wide polygenic risk (Niemi
et al., 2018) or other yet to be identified factors.
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